<DOC>
	<DOC>NCT00291005</DOC>
	<brief_summary>- To evaluate the overall tumor response rate in subjects with metastatic hormone refractory prostate cancer - To evaluate PSA (tumor marker) response rate - To evaluate safety</brief_summary>
	<brief_title>PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<criteria>Men with prostate adenocarcinoma with at least one metastatic lesion which is measurable and who progressed after prior hormonal therapy. 1.Body temperature &gt; 38 degree centigrade. 2.Prior radiotherapy to &gt; 25% of bone marrow. 3.Prior isotope therapy and/or brachytherapy 4.Prior gene therapy. 5.Active double cancer. 6.Known brain or leptomeningeal involvement. 7.History of hypersensitivity reaction to drug 8.Other serious illness or medical condition 9.Subjects whom the investigators consider inappropriate from social or medical aspects.</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>HRPC</keyword>
	<keyword>AIPC</keyword>
	<keyword>Hormone refractory</keyword>
	<keyword>Androgen independent</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Taxotere</keyword>
	<keyword>prednisolone</keyword>
</DOC>